Department / Division:
Medicine / Cardiology

Address:
DUMC 3701
200 Trent Drive, 1117 Davison Building
Durham, NC 27710

Appointment Telephone:
919-681-5816

Office Telephone:
919-668-8820

Fax Telephone:
919-668-7103

• MD, Duke University School of Medicine, 1978

• Medicine, University of California, San Francisco Medical Center, 1979-1980
• Cardiology, Duke University Medical Center, 1980-1983

Clinical Interests:
Chronic coronary artery disease, heart failure, acute coronary syndromes

Research Interests:
Robert Califf, MD, is the Donald F. Fortin, MD, Professor of Cardiology, Vice Chancellor for Clinical Research and Director of the Duke Translational Medicine Institute.  He is also Professor of Medicine in the Division of Cardiology and remains a practicing cardiologist.  Dr. Califf has led some of the best-known clinical trials and health outcomes studies in cardiovascular medicine and has published over 800 peer reviewed original articles in collaboration with his colleagues.  He is currently the 7th most frequently cited author in the field of medicine globally.  He is considered a leader in the fields of quality of care, technology development and health policy.  He has served on numerous committees and panels assisting in the development of health policy including the Cardiorenal Panel of the FDA and multiple Institute of Medicine Committees, including the Committee on Identifying and Preventing Medication Errors, the Forum on Drug Discovery and Translation and the Science Board of the FDA.  He was the founding Director of the Coordinating Center for the Centers for Education and Research in Therapeutics (CERTs), a public/private partnership focused on the safety of medical products.  After 10 years as founding director of the DCRI he has founded the Duke Translational Medicine Institute, which encompasses the spectrum of translational research at Duke.

Representative Publications:
Topol EJ, Califf RM, Van de Werf F, Simoons M, Hampton J, Lee KL, White H, Simes J, Armstrong PW, for the Virtual Coordinating Center for Global Collaborative Cardiovascular Research (VIGOUR) Group. Perspective on large-scale cardiovascular clinical trials in the new millennium. Circulation 1997;95:1072-1082 (337) (1997)

The IMPACT II Investigators. (Tcheng JE, Lincoff AM, Sigmon KN, Lee KL, Kitt MM, Califf RM, Topol EJ, Juran N, Worley S. Tuzi J, Hollywood L, Kleiman NS, Ali MN, Rose D, Kereiakes DJ, Higby N, George J, Heibrunn S, Roncevich T, Burnheimer B, Ivanhoe R, Meade L, Rund M, Tannenaum M, Stangle D, et al.) Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention - IMPACT II. Lancet 1997;349(9063):1422-1428. (371) (1997)

The GUSTO III (The Global Use of Strategies to Open Occluded Coronary Arteries) Investigators (Eric J. Topol). A comparison of Reteplase with Alteplase for acute myocardial infarction. N Eng J Med 1997;337:1118-1123. (454) (1997)

The EPILOG Investigators (Topol EJ, Califf RM, Lincoff AM, Tcheng JE, Cabot CF, Weisman HF, Kereiakes D, Lausten D, Runyon JP, Howard W, Kelly T, Muncy D, Timmis G, Safian M, Davey D, Kleiman NS, Rose D, Basinger L, Rouse C, Dramer J, Wilson R, Talley JD, Boyles M, Navetta FI, Lebeuf R, Kraft P, et al.) Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336(24):1689-1696. (420) (1997)

The BARI Investigators. The Bypass Angioplasty Revascularization Investigation (BARI): Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease: A multicenter randomized trial JAMA 1997;277:715-721. (354) (1997)

Califf RM, Adams K, McKenna W, Gheorghiade M, Uretsky B, McNulty SE, Darius H, Schulman KA, Zannad F, Handberg-Thurmond E, Harrell Jr. FE, Wheeler W, Soler-Soler J, Swedburg K. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan international randomized survival trial (FIRST). Am Heart J 1997;134:44-54. (191) (1997)